Trial reportPloS one2018
Predictive value of soluble ST2 in adolescent and adult patients with complex congenital heart disease.
Trial report in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Evolving Proteomic Biomarkers in Children with Congenital Heart Defects.Journal of cardiovascular development and disease · 2026Review
- Exploring Biomarkers in Congenital Heart Disease: A Case-Control Study of ST2 in Children with Atrial Septal Defects.International journal of molecular sciences · 2026Article
- Circulating Biomarkers in Failing Fontan Circulation: Current Evidence and Future Directions.Journal of cardiovascular development and disease · 2025Review
- The significance of serum sST2 and cfDNA in children with severe pneumonia complicated by myocardial damage.Journal of medical biochemistry · 2025Article
- Blood Biomarkers as a Non-Invasive Method for the Assessment of the State of the Fontan Circulation.Journal of clinical medicine · 2025Review
- Changes in blood biomarkers correlate with changes in cardiac size and function in patients with tetralogy of Fallot.International journal of cardiology. Congenital heart disease · 2024Article
- Does the ST2 Level in Pediatric Heart Failure Patients Correlate with Cardiovascular Events and Mortality?Children (Basel, Switzerland) · 2024Article
- Newborn Screening for High-Risk Congenital Heart Disease by Dried Blood Spot Biomarker Analysis.JAMA network open · 2024Article
- Preoperative sST2 levels relate to myocardial remodeling and cardiac function improvement after cardiac valve surgery.ESC heart failure · 2024Article
- Blood biomarkers to detect functional impairment in adult patients with repaired tetralogy of Fallot.International journal of cardiology. Congenital heart disease · 2023Article
- Review
- Biomarker sST2 in Adults with Transposition of the Great Arteries Palliated by Mustard Procedure: A Five-Year Follow-up.Pediatric cardiology · 2023Article
- Concentrations of Soluble Angiotensin Converting Enzyme 2 (sACE2) in Children and Adults with and without COVID-19.Journal of clinical medicine · 2022Article
- Soluble Isoform of Suppression of Tumorigenicity 2 (ST2) Biomarker in a Large Cohort of Healthy Pediatric Population: Determination of Reference Intervals.Journal of clinical medicine · 2022Article
- Determinants of soluble angiotensin-converting enzyme 2 concentrations in adult patients with complex congenital heart disease.Clinical research in cardiology : official journal of the German Cardiac Society · 2022Article
- Associations Between Blood Biomarkers, Cardiac Function, and Adverse Outcome in a Young Fontan Cohort.Journal of the American Heart Association · 2021Article
- Prognostic value of soluble ST2 in adults with congenital heart disease.Heart (British Cardiac Society) · 2019Article
- Micro-RNA 150-5p predicts overt heart failure in patients with univentricular hearts.PloS one · 2019Article
- Serum soluble suppression of tumorigenicity-2 level associates with severity of pulmonary hypertension associated with uncorrected atrial septal defect.Pulmonary circulationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSoluble suppression of tumorogenicity 2 (sST2) has been shown to be of prognostic value in patients with chronic and acute left heart failure. The present study aims to assess the predictive value of sST2 levels in adult patients with complex congenital heart disease (CHD).
methodsIn 169 consecutive patients with complex CHD and a mean age of 28.2 ± 12.0 years, sST2 levels were compared to 32 healthy controls and associated with clinical status as well as the occurrence of major adverse cardiac events (MACE). Mean follow-up time was 35.6 ± 24.9 months.
resultsIn CHD patients, median sST2 levels were 29.7 ng/ml compared to 26.4 ng/ml in healthy controls (p = 0.007) and increased with different types of CHD and the severity of MACE. According to ROC analysis, the most important predictors of acute heart/Fontan failure were NYHA class III/IV (AUC 0.804, p<0.001, CI 0.668-0.941), NT-proBNP levels (AUC 0.794, p<0.001, CI 0.640-0.948), γGT levels (AUC 0.793, p<0.001, CI 0.678-0.909) and sST2 levels (AUC 0.742, p = 0.004, CI 0.626-0.858), with NYHA class III/IV as the strongest independent predictor (p<0.001). All-cause mortality was best predicted by sST2 levels (AUC 0.890, p<0.001, CI 0.741-1.000), NT-proBNP levels (AUC 0.875, p = 0.001, CI 0.766-0.984) and NYHA class III/IV (AUC 0.837, p = 0.003, CI 0.655-1.000) with sST2 as the strongest independent predictor (p<0.001). Moreover, AUC increased to 0.918 combining both biomarkers and net reclassification improved with the addition of sST2.
conclusionIn patients with complex CHD, sST2 may have additive value to natriuretic peptides for the prediction of all-cause mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.